This recent transaction increases Andre Godin’s holding in the company by 10.97% to a total of $75.84K.
Based on IntelGenx Technologies’ latest earnings report for the quarter ending December 31, the company posted quarterly revenue of $651K and GAAP net loss of $2.5 million. In comparison, last year the company earned revenue of $239K and had a GAAP net loss of $2.26 million. Currently, IntelGenx Technologies has an average volume of 11.03K.
Starting in May 2018, IGXT received 12 Buy ratings in a row.
Andre Godin’s trades have generated a 33.0% average return based on past transactions. DailyInsider proprietary algorithm detects trades by the most influential insiders and selects attractive trading opportunities daily. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
IntelGenx Technologies Corp. is a oral drug delivery company, which focuses on the development and manufacturing of pharmaceutical oral films based on its proprietary VersaFilm technology platform. Its products include rizaport, tadalafil, loxapine, and montelukast.